SHANGHAI, CHINA – November 11, 2025 — Mabwell (688062.SH), an innovative biopharmaceutical company specializing in biologics for major diseases, announced positive Phase III clinical trial results for 9MW3011, its novel anti–IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis. The pivotal study demonstrated high efficacy, rapid onset, and a favorable safety profile, reinforcing Mabwell’s commitment to advancing evidence-based, patient-centric innovation in immunology and dermatology.
Science Significance
The results validate the scientific rationale behind 9MW3011’s precision-engineered antibody design. As a humanized monoclonal antibody targeting the p19 subunit of interleukin-23, it selectively blocks the IL-23/Th17 axis, a critical pathway in autoimmune inflammation. In the Phase III study, > 80% of patients achieved PASI 90 and > 55% achieved PASI 100 (complete clearance) by Week 16. Pharmacokinetic profiles confirmed a long half-life and sustained serum exposure, supporting convenient maintenance dosing. Backed by Mabwell’s proprietary cell expression platform, the therapy offers high affinity and low immunogenicity with global-scale manufacturing potential. These scientific findings underline Mabwell’s growing R&D strength and position China as an emerging leader in next-generation cytokine-targeted biologics.
Regulatory Significance
The successful completion of this Phase III trial positions 9MW3011 for regulatory submission to China’s National Medical Products Administration (NMPA) and potential global filings. Mabwell plans to submit a Biologics License Application (BLA) in early 2026. The data package was developed in accordance with ICH E6 (R3) Good Clinical Practice and global immunology guidelines, meeting standards recognized by the EMA and U.S. FDA. Given the significant unmet clinical need in psoriasis and the strong efficacy signals, the therapy may qualify for priority review or breakthrough designation, accelerating patient access. The program also showcases the increasing maturity of China’s clinical and regulatory ecosystem in biologics development, bridging domestic innovation with global evaluation standards.
Business Significance
Advertisement
The positive Phase III results significantly enhance Mabwell’s pipeline value and commercial readiness in the autoimmune and dermatology segments. Psoriasis biologics represent a fast-growing global market expected to reach USD 25 billion by 2030, driven by IL-23 and IL-17 therapies. Mabwell’s competitive advantage lies in its innovative molecule, durable response, and cost-effective manufacturing enabled by in-house CHO cell expression and downstream technologies. The clinical success bolsters partnership potential for co-development and regional licensing, while strengthening Mabwell’s long-term strategy to build a diversified portfolio in immunology and chronic inflammatory diseases. This achievement further solidifies Mabwell’s status as a rising global player in the biologic therapeutics landscape.
Patients’ Significance
For patients with moderate-to-severe plaque psoriasis, the Phase III outcomes represent a potential breakthrough in disease control and quality of life. Psoriasis is a chronic autoimmune condition that causes painful, visible lesions and significant emotional distress. The high PASI 90/100 rates, combined with a rapid onset and sustained clearance, suggest that 9MW3011 could provide patients with long-term remission and fewer injections. The drug’s safety profile—characterized by low immunogenicity and minimal injection-site reactions—supports its suitability for chronic use. By emphasizing affordability and domestic production, Mabwell also improves access to advanced biologic therapies for Chinese patients who previously faced financial barriers to treatment.
Policy Significance
The advancement of 9MW3011 aligns with national and international health policies promoting innovation-driven clinical research and equitable biologic access. In China, government reforms to accelerate drug approvals and support domestic R&D have enabled companies like Mabwell to bring world-class biologics to market faster. This success reinforces the “Healthy China 2030” policy goals by enhancing patient access to innovative therapies. Globally, the achievement reflects a growing trend of collaborative regulatory harmonization and biotherapeutic diversification, ensuring that next-generation IL-23 inhibitors like 9MW3011 can compete internationally while supporting sustainable healthcare systems.
The positive Phase III results for Mabwell’s 9MW3011 mark a significant milestone in the clinical development of next-generation biologics for autoimmune diseases. By combining strong efficacy, safety, and patient accessibility, Mabwell is poised to reshape the therapeutic landscape of psoriasis and beyond. This achievement demonstrates how rigorous clinical research and innovative biotechnology can advance global health objectives, paving the way for a new era of precision immunotherapy that delivers lasting benefits to patients worldwide.
Source: Mabwell press release
